Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina

被引:273
作者
Allen, KB
Dowling, RD
Fudge, TL
Schoettle, GP
Selinger, SL
Gangahar, DM
Angell, WW
Petracek, MR
Shaar, CJ
O'Neill, WW
机构
[1] St Vincent Hosp & Indiana Heart Inst, Dept Cardiothorac Surg, Indianapolis, IN USA
[2] Univ Louisville & Jewish Heart & Lung Inst, Dept Cardiothorac Surg, Louisville, KY USA
[3] Terrebonne Hosp, Dept Cardiothorac Surg, Houma, LA USA
[4] Methodist Hosp, Dept Cardiothorac Surg, Memphis, TN USA
[5] Sacred Heart Med Ctr, Dept Cardiothorac Surg, Spokane, WA USA
[6] Bryan Mem Hosp, Dept Cardiothorac Surg, Lincoln, NE USA
[7] Tampa Gen Hosp, Dept Cardiothorac Surg, Tampa, FL 33606 USA
[8] St Thomas Heart Inst, Nashville, TN USA
[9] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA
关键词
D O I
10.1056/NEJM199909303411403
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transmyocardial revascularization involves the creation of channels in the myocardium with a laser to relieve angina. We compared the safety and efficacy of transmyocardial revascularization performed with a holmium laser with those of medical therapy in patients with refractory class IV angina (according to the criteria of the Canadian Cardiovascular Society). Methods In a prospective study conducted between March 1996 and July 1998 at 18 centers, 275 patients with medically refractory class IV angina and coronary disease that could not be treated with percutaneous or surgical revascularization were randomly assigned to receive transmyocardial revascularization followed by continued medical therapy (132 patients) or medical therapy alone (143 patients). Results After one year of follow-up, 76 percent of the patients who had undergone transmyocardial revascularization had improvement in angina (a reduction of two or more classes), as compared with 32 percent of the patients who received medical therapy alone (P<0.001). Kaplan-Meier survival estimates at one year (based on an intention-to-treat analysis) were similar for the patients assigned to undergo transmyocardial revascularization and those assigned to receive medical therapy alone (84 percent and 89 percent, respectively; P = 0.23). At one year, the patients in the transmyocardial-revascularization group had a significantly higher rate of survival free of cardiac events (54 percent, vs. 31 percent in the medical-therapy group; P<0.001), a significantly higher rate of freedom from treatment failure (73 percent vs. 47 percent, P<0.001), and a significantly higher rate of freedom from cardiac-related rehospitalization (61 percent vs. 33 percent, P<0.001). Exercise tolerance and quality-of-life scores were also significantly higher in the transmyocardial-revascularization group than in the medical-therapy group (exercise tolerance, 5.0 MET [metabolic equivalent] vs. 3.9 MET; P = 0.05; quality-of-life score, 21 vs. 12; P = 0.003). However, there were no differences in myocardial perfusion between the two groups, as assessed by thallium scanning. Conclusions Patients with refractory angina who underwent transmyocardial revascularization and received continued medical therapy, as compared with similar patients who received medical therapy alone, had a significantly better outcome with respect to improvement in angina, survival free of cardiac events, freedom from treatment failure, and freedom from cardiac-related rehospitalization. (N Engl J Med 1999;341:1029-36.) (C)1999, Massachusetts Medical Society.
引用
收藏
页码:1029 / 1036
页数:8
相关论文
共 27 条
[1]   Cardiac sympathetic denervation after transmyocardial laser revascularization [J].
Al-Sheikh, T ;
Allen, KB ;
Straka, SP ;
Heimansohn, DA ;
Fain, RL ;
Hutchins, GD ;
Sawada, SG ;
Zipes, DP ;
Engelstein, ED .
CIRCULATION, 1999, 100 (02) :135-140
[2]  
Allen KB, 1998, CIRCULATION, V98, P476
[3]  
Allen KB, 1998, EUR J CARDIO-THORAC, V14, pS100
[4]   The development of a new blood supply to the heart by operation [J].
Beck, CS .
ANNALS OF SURGERY, 1935, 102 :801-813
[5]   Histologic appearance of transmyocardial laser channels after 4-1/2 weeks [J].
Burkhoff, D ;
Fisher, PE ;
Apfelbaum, M ;
Kohmoto, T ;
DeRosa, CM ;
Smith, CR .
ANNALS OF THORACIC SURGERY, 1996, 61 (05) :1532-1534
[6]   Transmyocardial laser revascularization: Clinical experience with twelve-month follow-up [J].
Cooley, DA ;
Frazier, OH ;
Kadipasaoglu, KA ;
Lindenmeir, MH ;
Pehlivanoglu, S ;
Kolff, JW ;
Wilansky, S ;
Moore, WH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (04) :791-799
[7]  
COOLEY DA, 1994, TEX HEART I J, V21, P220
[8]  
Dowling RD, 1998, CIRCULATION, V98, pII73
[9]  
*FOOD DRUG ADM, 1997, CIRC SYST DEV PAN M, P15
[10]  
*FOOD DRUG ADM, 1998, CIRC SYST DEV PAN M, P30